Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease

Acetylcholinesterase inhibitors from plants

Mukherjee, P. K., Kumar, V., Mal, M., & Houghton, P. J. (2007) · Phytomedicine · doi:10.1016/j.phymed.2007.02.002 · Cited by 809 · see citing works

The Lycopodium alkaloids

Ma, R., & Gang, D. R. (2004) · Natural Product Reports · doi:10.1039/b409720n · Cited by 660 · see citing works

THE ACTION OF CERTAIN ESTERS AND ETHERS OF CHOLINE, AND THEIR RELATION TO MUSCARINE

Dale, H. H. (1914) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)08268-0 · Cited by 658 · see citing works

The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity

Liu, J.-S., Zhu, Y.-L., Yu, C., Zhou, Y.-Z., Han, Y.-Y., Wu, F.-W., & Qi, B.-F. (1986) · Canadian Journal of Chemistry · doi:10.1139/v86-137 · Cited by 476 · see citing works

Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function

Howes, M. R., & Houghton, P. J. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00128-x · Cited by 443 · see citing works

Physostigmine: Improvement of Long-Term Memory Processes in Normal Humans

Davis, K. L., Mohs, R. C., Tinklenberg, J. R., Pfefferbaum, A., Hollister, L. E., & Kopell, B. S. (1978) · Science · doi:10.1126/science.351807 · Cited by 442 · see citing works

Properties of Neuronal Nicotinic Acetylcholine Receptors: Pharmacological Characterization and Modulation of Synaptic Function,

Albuquerque, E. X., Alkondon, M., Pereira, E. F. R., Castro, N. G., Schrattenholz, A. S., Barbosa, C. T. F., Bonfante-Cabarcas, R. A., Aracava, Y., Eisenberg, H. M., & Maelicke, A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36503-6 · Cited by 436 · see citing works

Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease

Wilkinson, D. G., Francis, P. T., Schwam, E. M., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365 · see citing works

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease

Coyle, J. T., & Kershaw, P. R. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 337 · see citing works

Plants traditionally used in age related brain disorders—A survey of ethnobotanical literature

Adams, M. A., Gmünder, F., & Hamburger, M. O. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.07.016 · Cited by 328 · see citing works

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease

Polinsky, R. J. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80127-6 · Cited by 323 · see citing works

Chapter 53: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease

Enz, A., Amstutz, R., Boddeke, H. W. G. M., Gmelin, G., & Malanowski, J. (1993) · Progress in brain research · doi:10.1016/s0079-6123(08)62429-2 · Cited by 301 · see citing works

Oral physostigmine and lecithin improve memory in Alzheimer disease

Thal, L. J., Fuld, P. A., Masur, D. M., & Sharpless, N. S. (1983) · Annals of Neurology · doi:10.1002/ana.410130504 · Cited by 284 · see citing works

Enhancement of memory processes in Alzheimer's disease with multiple- dose intravenous physostigmine

Davis, K. L., & Mohs, R. C. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.11.1421 · Cited by 268 · see citing works

Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition

Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 261 · see citing works

Oral physostigmine treatment of patients with Alzheimer's disease

Mohs, R. C., Davis, B. J., Johns, C. A., Mathé, A. A., GREENWALD, B. S., Horvath, T., & Davis, K. L. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.1.28 · Cited by 240 · see citing works

Natural Products and Derivatives Affecting Neurotransmission Relevant to Alzheimer’s and Parkinson’s Disease

Houghton, P. J., & Howes, M. R. (2005) · Neurosignals · doi:10.1159/000085382 · Cited by 227 · see citing works

Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.

Schrattenholz, A. S., Pereira, E. F. R., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08675-4 · Cited by 226 · see citing works

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo

Thomsen, T., & Kewitz, H. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90429-u · Cited by 207 · see citing works

Acetylcholinesterase Inhibition in Alzheimers Disease

Ibach, B., & Haen, E. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043386509 · Cited by 190 · see citing works

Current approaches in the treatment of Alzheimer's disease

Shah, R. S., Lee, H., Zhu, X., Perry, G. L., Smith, M. A., & Castellani, R. J. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.005 · Cited by 176 · see citing works

Natural Products and their Derivatives as Cholinesterase Inhibitors in the Treatment of Neurodegenerative Disorders: An Update

Loizzo, M. R., Tundis, R., Menichini, F., & Menichini, F. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784310422 · Cited by 173 · see citing works

Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease

Potkin, S. G., Anand, R., Fleming, K., Alva, G., Keator, D. B., Carreon, D., Messina, J. C., Wu, J. C., Hartman, R. D., & Fallon, J. H. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002528 · Cited by 158 · see citing works

Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A

Kozikowski, A. P., & Tückmantel, W. (1999) · Accounts of Chemical Research · doi:10.1021/ar9800892 · Cited by 150 · see citing works

Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging

Araujo, J. A., Studzinski, C. M., & Milgram, N. W. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.12.008 · Cited by 140 · see citing works

A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

Francis, P. T., Nordberg, A. K., & Arnold, S. E. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.010 · Cited by 140 · see citing works

Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by β-amyloid protein-(1–40) in rat

Wang, R., Zhang, H., & Tang, X. C. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01030-5 · Cited by 131 · see citing works

Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity

Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A., & Shimohama, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.132 · Cited by 124 · see citing works

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., & Zolnouni, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00645.x · Cited by 123 · see citing works

A review of rivastigmine: A reversible cholinesterase inhibitor

Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122 · see citing works

Medicinal Plants and Alzheimer's Disease: Integrating Ethnobotanical and Contemporary Scientific Evidence

Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P., & Perry, N. S. L. (1998) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.1998.4.419 · Cited by 113 · see citing works

Potent acetylcholinesterase inhibitors: design, synthesis, and structure–Activity relationships of bis-interacting ligands in the galanthamine series

Mary, A., Renko, D. Z., Guillou, C., & Thal, C. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00133-3 · Cited by 106 · see citing works

A total synthesis of (±)-huperzine A

Qian, L., & Ji, R. (1989) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)93719-0 · Cited by 100 · see citing works

In vitro production of huperzine A, a promising drug candidate for Alzheimer’s disease

Ma, R., & Gang, D. R. (2008) · Phytochemistry · doi:10.1016/j.phytochem.2008.04.017 · Cited by 96 · see citing works

Galanthamine, a Natural Product for the Treatment of Alzheimers Disease

Marco, L., & Carreiras, M. C. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906775245246 · Cited by 92 · see citing works

Treatment of acute colonic pseudo-obstruction with neostigmine1

Paran, H., Silverberg, D., Mayo, A., Shwartz, I., Neufeld, D. M., & Freund, U. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(99)00273-2 · Cited by 91 · see citing works

Effects of oral physostigmine in Alzheimer's disease

Stern, Y., Sano, M. C., & Mayeux, R. P. (1987) · Annals of Neurology · doi:10.1002/ana.410220305 · Cited by 88 · see citing works

Potent acetylcholinesterase inhibitors: design, synthesis and structure–activity relationships of alkylene linked bis-galanthamine and galanthamine–galanthaminium salts

Guillou, C., Mary, A., Renko, D. Z., Gras, E., & Thal, C. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00059-7 · Cited by 87 · see citing works

Long‐term administration of oral physostigmine in Alzheimer's disease

Stern, Y., Sano, M. C., & Mayeux, R. P. (1988) · Neurology · doi:10.1212/wnl.38.12.1837 · Cited by 85 · see citing works

Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.

Eskander, M. F., Nagykery, N., Leung, E., Khelghati, B., & Geula, C. (2005) · Brain Research · doi:10.1016/j.brainres.2005.08.039 · Cited by 84 · see citing works

Reversal of scopolamine-induced deficits in radial maze performance by (−)-huperzine A: comparison with E2020 and tacrine

Wang, T., & Tang, X. C. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00199-x · Cited by 82 · see citing works

Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats

Wang, L., Han, Y., & Tang, X. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00291-0 · Cited by 81 · see citing works

A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease

Thal, L. J., Schwartz, G. E., Sano, M. C., Weiner, M., Knopman, D. S., Harrell, L. E., Bodenheimer, S. L., Rossor, M. N., Philpot, M. P., Schor, J., et al. (1996) · Neurology · doi:10.1212/wnl.47.6.1389 · Cited by 80 · see citing works

Synthesis and evaluation of tacrine–Huperzine a hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of alzheimer’s disease

Badı́a, A., Baños, J.-E., Camps, P., Contreras, J., GOERBIG, D. M., Muñoz‐Torrero, D., Simón, M., & Vivas, N. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00015-7 · Cited by 80 · see citing works

N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum

Berkov, S. H., Codina, C. J., Viladomat, F., & Bastida, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.008 · Cited by 78 · see citing works

Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease

Lahiri, D. K., Farlow, M. R., Hintz, N., Utsuki, T., & Greig, N. H. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00309.x · Cited by 77 · see citing works

Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors

Carlier, P. R., Du, D., Han, Y., Liu, J., & Pang, Y. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00396-0 · Cited by 77 · see citing works

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

Thal, L. J., Ferguson, J. M., Mintzer, J. E., Raskin, A., & Targum, S. D. (1999) · Neurology · doi:10.1212/wnl.52.6.1146 · Cited by 74 · see citing works

Rodent models of memory dysfunction in Alzheimer's disease and normal aging: Moving beyond the cholinergic hypothesis

Ingram, D. K., Spangler, E. L., Iijima, S., Ikari, H., Kuo, H., Greig, N. H., & London, E. D. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00384-x · Cited by 70 · see citing works

Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine

Kamal, M. A., Greig, N. H., Alhomida, A. S., & Al‐Jafari, A. A. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00330-0 · Cited by 70 · see citing works

Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors

Jia, P. J., Sheng, R., Zhang, J., Fang, L., He, Q., Yang, B., & Hu, Y. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.04.018 · Cited by 70 · see citing works

New kilogram-synthesis of the anti-alzheimer drug (−)-galanthamine

Czollner, L., Frantsits, W., Küenburg, B., Hedenig, U., Fröhlich, J., & Jordis, U. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)00294-9 · Cited by 70 · see citing works

The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics

Greig, N. H., Micheli, E. D., Holloway, H. W., Yu, Q.-S., Utsuki, T., Perry, T., Ingram, D. K., Deutsch, J., Lahiri, D. K., & Soncrant, T. T. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00311.x · Cited by 69 · see citing works

The Identity of the Serotonin‐Sensitive Aryl Acylamidase with Acetylcholinesterase from Human Erythrocytes, Sheep Basal Ganglia and Electric Eel

George, S. T., & Balasubramanian, A. S. (1980) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1980.tb04967.x · Cited by 67 · see citing works

Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type

Agid, Y., Dubois, B., Anand, R., & Gharabawi, G. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85048-0 · Cited by 64 · see citing works

The Aryl Acylamidases and Their Relationship to Cholinesterases in Human Serum, Erythrocyte and Liver

George, S. T., & Balasubramanian, A. S. (1981) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1981.tb06447.x · Cited by 64 · see citing works

Indicators of neuroprotection with galantamine

Geerts, H. (2004) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2004.11.002 · Cited by 61 · see citing works

Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo

Tang, X.-C., Kindel, G. H., Kozikowski, A. P., & Hanin, I. (1994) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(94)01182-6 · Cited by 60 · see citing works

Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase

Perola, E., Cellai, L., Lamba, D., Filocamo, L., & Brufani, M. (1997) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(97)00133-7 · Cited by 60 · see citing works

The Early Toxicology of Physostigmine

Proudfoot, A. T. (2006) · Toxicological Reviews · doi:10.2165/00139709-200625020-00004 · Cited by 59 · see citing works

Total synthesis of (+)-galanthamine starting from d-glucose

Tanimoto, H., Kato, T., & Chida, N. (2007) · Tetrahedron Letters · doi:10.1016/j.tetlet.2007.07.042 · Cited by 56 · see citing works

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease

Imbimbo, B. P., Martelli, P. R., Troetel, W. M., Lucchelli, F., Lucca, U., Thal, L. J., & The Eptastigmine Study Group (1999) · Neurology · doi:10.1212/wnl.52.4.700 · Cited by 55 · see citing works

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States

Migliaccio–Walle, K., Getsios, D., Jaime, J., Ishak, K. J., O’Brien, J. A., & Papadopoulos, G. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80171-6 · Cited by 54 · see citing works

Neostigmine for the treatment of pediatric acute colonic pseudo-obstruction

Gmora, S. B., Poenaru, D., & Tsai, E. (2002) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2002.35438 · Cited by 48 · see citing works

Postoperative analgesia by intraarticular and epidural neostigmine following knee surgery

Lauretti, G. R., de Oliveira, R. D. V. C., Perez, M. V., & Paccola, C. A. J. (2000) · Journal of Clinical Anesthesia · doi:10.1016/s0952-8180(00)00189-6 · Cited by 46 · see citing works

Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase

Ikari, H., Spangler, E. L., Greig, N. H., Pei, X., Brossi, A. R., Speer, D. L., Patel, N., & Ingram, D. K. (1995) · Neuroreport · doi:10.1097/00001756-199502000-00019 · Cited by 44 · see citing works

Characterisation of the anticholinesterase activity of two new tacrine–huperzine A hybrids

Alcalá, M. D. M., Vivas, N. M., Camps, P., Muñoz‐Torrero, D., & Badı́a, A. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00071-6 · Cited by 43 · see citing works

Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis and Biological Properties

Brossi, A., PEI, X. ‐., & Greig, N. (1996) · Australian Journal of Chemistry · doi:10.1071/ch9960171 · Cited by 41 · see citing works

Inhibition of Cholinesterase-associated Aryl Acylamidase Activity by Anticholinesterase Agents: Focus on Drugs Potentially Effective in Alzheimer’s Disease

Costagli, C., & Galli, A. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00676-x · Cited by 40 · see citing works

Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by a Novel Derivative of Physostigmine: Phenserine

Al‐Jafari, A. A., Kamal, M. A., Greig, N. H., Alhomida, A. S., & Perry, E. R. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8931 · Cited by 40 · see citing works

Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease

Mustazza, C., Borioni, A., Giudice, M. R. D., GATTA, F., Ferretti, R., Meneguz, A., Volpe, M. T., & Lorenzini, P. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01324-1 · Cited by 39 · see citing works

A concise and convergent (formal) total synthesis of huperzine A

Lucey, C., Kelly, S. A., & Mann, J. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b615059d · Cited by 37 · see citing works

Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity

Zhao, H., & Li, X. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00093-0 · Cited by 36 · see citing works

Comparison of postoperative analgesic effects of preemptively used epidural ketamine and neostigmine

Kırdemir, P., Özkoçak, I., Demir, T., & Göğüş, N. (2000) · Journal of Clinical Anesthesia · doi:10.1016/s0952-8180(00)00216-6 · Cited by 34 · see citing works

Synthesis and structure–activity relationships of open D-Ring galanthamine analogues

Herlem, D., Martin, M., Thal, C., & Guillou, C. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00397-4 · Cited by 34 · see citing works

Variation in huperzine A and B in Australasian Huperzia species

Goodger, J. Q. D., Whincup, A. L., Field, A. R., Holtum, J. A. M., & Woodrow, I. E. (2008) · Biochemical Systematics and Ecology · doi:10.1016/j.bse.2008.05.006 · Cited by 33 · see citing works

Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update

Tumiatti, V., Bolognesi, M. L., Minarini, A., Rosini, M., Milelli, A., Matera, R., & Melchiorre, C. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.4.387 · Cited by 33 · see citing works

Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring

Campiani, G., Kozikowski, A. P., Wang, S., Ming, L., Nacci, V., Saxena, A., & Doctor, B. P. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00229-7 · Cited by 29 · see citing works

Inflammation and aging: Can endocannabinoids help?

Marchalant, Y., Brothers, H. M., & Wenk, G. L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.004 · Cited by 29 · see citing works

Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats

Dahlin, M., & Björk, E. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00612-8 · Cited by 27 · see citing works

A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer’s Disease

Imbimbo, B. P., Troetel, W. M., Martelli, P., & Lucchelli, F. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017208 · Cited by 27 · see citing works

(−)-9-Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats

Lamirault, L., Guillou, C., Thal, C., & Simon, H. (2003) · Neurobiology of Learning and Memory · doi:10.1016/s1074-7427(03)00064-9 · Cited by 23 · see citing works

Synthesis and acetylcholinesterase inhibitory activity of huperzine A—E2020 combined compound

Zeng, F., Jiang, H., Zhai, Y., Zhang, H., Chen, K., & Ji, R. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00597-1 · Cited by 22 · see citing works

Synthesis and acetylcholinesterase inhibition of 5-desamino huperzine A derivatives

Hoegenauer, K., Baumann, K., Enz, A., & Mulzer, J. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00518-2 · Cited by 21 · see citing works

New Syntheses of rac-Huperzine A and its rac-7-Ethyl-Derivative. Evaluation of Several Huperzine A Analogues as Acetylcholinesterase Inhibitors

Camps, P., Contreras, J., Achab, R. E., Morral, J., Muñoz‐Torrero, D., Font‐Bardía, M., Soláns, X., Badı́a, A., & Vivas, N. M. (2000) · Tetrahedron · doi:10.1016/s0040-4020(00)00363-x · Cited by 19 · see citing works

Eptastigmine improves eight-arm radial maze performance in aged rats

Braida, D., Ottonello, F., & Sala, M. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0706 · Cited by 15 · see citing works

The pharmacology of novel acetylcholinesterase inhibitors, (±)-huprines Y and X, on the Torpedo electric organ

Ros, E., Aleu, J., de Aranda, I. G., Muñoz‐Torrero, D., Camps, P., Badı́a, A., Marsal, J., & Solsona, C. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01028-7 · Cited by 14 · see citing works

A convergent approach to huperzine A and analogues

Foricher, Y. J. Y., & Mann, J. (2000) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)00085-x · Cited by 14 · see citing works

Neostigmine competitively inhibited nicotinic acetylcholine receptors in sympathetic neurons

Jian-quan, Z., He, X., Yang, A., & Liu, C.-G. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00043-5 · Cited by 12 · see citing works

Surprising discovery with Alzheimer's medication

Thacker, P. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02685-0 · Cited by 12 · see citing works

NXX-066 in patients with Alzhemer's Disease: A bridging study

Sramek, J. J., Hourani, J., Jhee, S. S., & Cutler, N. R. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00053-3 · Cited by 11 · see citing works

4'-Hydroxyphenylcarbamates of (3aS)-Eseroline and (3aS)-N(1)-Noreseroline: Potential Metabolites of the Alzheimer's Anticholinesterase Drug Phenserine

Greig, N. H., Yu, Q., Holloway, H. W., & Brossi, A. R. (1999) · Heterocycles · doi:10.3987/com-98-s(h)3 · Cited by 11 · see citing works

Synthesis and acetylcholinesterase inhibitory activity of (±)-14-fluorohuperzine A

Zeng, F., Hualiang, J., Xican, T., Chen, K., & Ru-yun, J. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00280-7 · Cited by 10 · see citing works

Effects of (±)-huprine Y and (±)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors

Alcala, M. M., Maderuelo, A., Vivas, N. M., Camps, P., Muñoz‐Torrero, D., Clos, M. V., & Badı́a, A. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.044 · Cited by 9 · see citing works

Naturally occurring multipotent anti-Alzheimer’s agents

Zhang, H., Yang, D., & Ji, H. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.3.269 · Cited by 8 · see citing works

Physostigmine: short history and its impact on anaesthesiology of present days

Dworacek, B., & Rupreht, J. (2002) · International Congress Series · doi:10.1016/s0531-5131(02)00705-7 · Cited by 7 · see citing works

Rivastigmine in the Treatment of Alzheimer’s Disease

Deleu, D. (2001) · European Neurology · doi:10.1159/000050779 · Cited by 4 · see citing works

Acetylcholinesterase inhibitor SDZ ENA 713 (Rivastigmine) increases brain pyrrolidone carboxyl peptidase activity

Ramı́rez-Expósito, M. J., Robert‐Baudouy, J., Mayas, M. D., García, M. J. G., Ramírez, M. R., & Martı́nez-Martos, J. M. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00106-7 · Cited by 3 · see citing works

ChemInform Abstract: Synthetic Studies of Huperzine A and Its Fluorinated Analogues. Part 2. Synthesis and Acetylcholinesterase Inhibitory Activity of Novel Fluorinated Huperzine A Analogues.

Kaneko, S., Nakajima, N., Shikano, M., Katoh, T.-I., & Terashima, S. (1998) · ChemInform · doi:10.1002/chin.199833263 · Cited by 2 · see citing works

New Acetylcholinesterase Inhibitors for Alzheimer's Disease

Mehta, M., Adem, A., & Sabbagh, M. N. (2011) · International Journal of Alzheimer s Disease · doi:10.1155/2012/728983 · Cited by 436 · see citing works

Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection

Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., & Singh, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.050 · Cited by 364 · see citing works

Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders

Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., & Li, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23247 · Cited by 352 · see citing works

Natural AChE Inhibitors from Plants and their Contribution to Alzheimer’s Disease Therapy

Murray, A. P., Faraoni, M. B., Castro, M., Alza, N. P., & Cavallaro, V. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040004 · Cited by 352 · see citing works

Management of oxidative stress and other pathologies in Alzheimer’s disease

Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02538-y · Cited by 303 · see citing works

Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms

Matés, J. M., Segura, J. A., Alonso, F. J., & Márquez, J. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.07.028 · Cited by 286 · see citing works

Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics

Cassidy, L., Fernandez, F., Johnson, J. B., Naiker, M., Owoola, A. G., & Broszczak, D. A. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102294 · Cited by 283 · see citing works

Medicinal Plants and Dementia Therapy: Herbal Hopes for Brain Aging?

Perry, E. K., & Howes, M. R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00202.x · Cited by 160 · see citing works

Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy

Arya, A., Chahal, R., Rao, R., Rahman, M. H., Kaushik, D., Akhtar, M. F., Saleem, A., Khalifa, S. M. A., El-Seedi, H. R., Kamel, M., et al. (2021) · Biomolecules · doi:10.3390/biom11030350 · Cited by 111 · see citing works

Pharmacological effects of Catharanthus roseus root alkaloids in acetylcholinesterase inhibition and cholinergic neurotransmission

Pereira, D. M., Ferreres, F., Oliveira, J. M. A., Gaspar, L., Faria, J. R. C., Valentão, P., Sottomayor, M., & Andrade, P. B. (2009) · Phytomedicine · doi:10.1016/j.phymed.2009.10.008 · Cited by 106 · see citing works

Natural cholinesterase inhibitors from marine organisms

Moodie, L. W. K., Sepčić, K., Turk, T., Frangež, R., & Svenson, J. (2019) · Natural Product Reports · doi:10.1039/c9np00010k · Cited by 102 · see citing works

Investigation on chemical composition, anticholinesterase and antioxidant activities of extracts and essential oils of Turkish Pinus species and pycnogenol

Ustun, O., Şenol, F. S., Kürkçüoğlu, M., Orhan, İ. E., Kartal, M., & Başer, K. H. C. (2012) · Industrial Crops and Products · doi:10.1016/j.indcrop.2012.01.016 · Cited by 101 · see citing works

Dietary polyunsaturated fatty acids improve cholinergic transmission in the aged brain

Willis, L., Shukitt‐Hale, B., & Joseph, J. A. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0141-6 · Cited by 60 · see citing works

Profiling of in vitro neurobiological effects and phenolic acids of selected endemic Salvia species

Orhan, İ. E., Şenol, F. S., Öztürk, N., Akaydın, G., & Şener, B. (2011) · Food Chemistry · doi:10.1016/j.foodchem.2011.11.119 · Cited by 60 · see citing works

In vitro hypoglycemic, antioxidant and antineurodegenerative activity of chokeberry (Aronia melanocarpa) leaves

Zdunić, G. M., Aradski, A. A., Gođevac, D. M., Živković, J., Duletić-Laušević, S. N., Krstić‐Milošević, D., & Šavikin, K. (2020) · Industrial Crops and Products · doi:10.1016/j.indcrop.2020.112328 · Cited by 60 · see citing works

Chemical composition and biological activity of Capparis spinosa L. from Lipari Island

Mollica, A., Stefanucci, A., Macedonio, G., Locatelli, M., Luisi, G., Novellino, E., & Zengin, G. (2018) · South African Journal of Botany · doi:10.1016/j.sajb.2018.02.397 · Cited by 58 · see citing works

Bringing natural products into the fold – exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases

Joyner, P. M., & Cichewicz, R. H. (2010) · Natural Product Reports · doi:10.1039/c0np00017e · Cited by 54 · see citing works

In vitro prospective effects of various traditional herbal coffees consumed in Anatolia linked to neurodegeneration

Şekeroğlu, N., Şenol, F. S., Orhan, İ. E., Gülpınar, A. R., Kartal, M., & Şener, B. (2011) · Food Research International · doi:10.1016/j.foodres.2011.10.008 · Cited by 50 · see citing works

A mechanistic investigation on anticholinesterase and antioxidant effects of rose (Rosa damascena Mill.)

Şenol, F. S., Orhan, İ. E., Kürkçüoğlu, M., Khan, M. T. H., Altintas, A., Şener, B., & Başer, K. H. C. (2013) · Food Research International · doi:10.1016/j.foodres.2013.05.031 · Cited by 48 · see citing works

Physostigmine: A Plant Alkaloid Isolated from Physostigma venenosum: A Review on Pharmacokinetics, Pharmacological and Toxicological Activities

Batiha, G. E., Alkazmi, L. M., Nadwa, E. H., Rashwan, E. K., Beshbishy, A. M., Shaheen, H. M., & Wasef, L. (2020) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v10i1-s.3866 · Cited by 47 · see citing works

Comparative studies on Turkish and Indian Centella asiatica (L.) Urban (gotu kola) samples for their enzyme inhibitory and antioxidant effects and phytochemical characterization

Orhan, I. E., Atasu, E., Senol, F. S., Ozturk, N., Demirci, B., Das, K., & Sekeroglu, N. (2013) · Industrial Crops and Products · doi:10.1016/j.indcrop.2013.03.022 · Cited by 44 · see citing works

Cognitive Enhancing and Antioxidative Potentials of Velvet Beans (Mucuna pruriens) and Horseradish (Moringa oleifera) Seeds Extracts: A Comparative Study

Adefegha, S. A., Oboh, G., Oyeleye, S. I., Dada, F. A., Ejakpovi, I. I., & Boligon, A. A. (2016) · Journal of Food Biochemistry · doi:10.1111/jfbc.12292 · Cited by 43 · see citing works

Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's

Dhanjal, J. K., Sharma, S., Grover, A., & Das, A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.02.010 · Cited by 39 · see citing works

Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors

Orhan, İ. E., & Gülcan, H. O. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150427113103 · Cited by 39 · see citing works

Plant-derived acetylcholinesterase inhibitory alkaloids for the treatment of Alzheimer's disease

Dall’Acqua, S. (2013) · Botanics Targets and Therapy · doi:10.2147/btat.s17297 · Cited by 37 · see citing works

Molecular modeling and in vitro approaches towards cholinesterase inhibitory effect of some natural xanthohumol, naringenin, and acyl phloroglucinol derivatives

Orhan, İ. E., Jędrejek, D., Şenol, F. S., Salmas, R. E., Durdağı, S., Kowalska, I., Pecio, Ł., & Oleszek, W. A. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.03.009 · Cited by 35 · see citing works

2-Arylbenzofurans from Artocarpus lakoocha and methyl ether analogs with potent cholinesterase inhibitory activity

Namdaung, U., Athipornchai, A., Khammee, T., Kuno, M., & Suksamrarn, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.019 · Cited by 34 · see citing works

Insights into the Pathophysiology of Alzheimer’s Disease and Potential Therapeutic Targets: A Current Perspective

Kumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 36 · see citing works

Insight into anticholinesterase and antioxidant potential of thirty-four Rosaceae samples and phenolic characterization of the active extracts by HPLC

Ekin, H. N., Gökbulut, A., Aydın, Z. U., Dönmez, A. A., & Orhan, İ. E. (2016) · Industrial Crops and Products · doi:10.1016/j.indcrop.2016.06.029 · Cited by 33 · see citing works

Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer’s Disease - A Promising Natural Molecule or Fashion of the Day? - A Narrowed Review

Orhan, İ. E. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666201119153807 · Cited by 34 · see citing works

Current anti-Alzheimer’s disease effect of natural products and their principal targets

Zhu, Y., Peng, L., Hu, J., Chen, Y., & Chen, F. (2019) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2019.03.1105 · Cited by 31 · see citing works

Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action

Orhan, İ. E. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040003 · Cited by 29 · see citing works

Evaluation of possible in vitro neurobiological effects of two varieties of Cupressus sempervirens (Mediterranean cypress) through their antioxidant and enzyme inhibition actions

Tümen, İ., Şenol, F. S., & Orhan, İ. E. (2012) · Turkish Journal of Biochemistry · doi:10.5505/tjb.2012.92400 · Cited by 29 · see citing works

Iron exposure modifies acetylcholinesterase activity in zebrafish (Danio rerio) tissues: distinct susceptibility of tissues to iron overload

Sant'Anna, M. C. B., Soares, V. D. M., Seibt, K. J., Ghisleni, G., Rico, E. P., Rosemberg, D. B., de Oliveira, J. R., Schröder, N., Bonan, C. D., & Bogo, M. R. (2010) · Fish Physiology and Biochemistry · doi:10.1007/s10695-010-9459-7 · Cited by 28 · see citing works

Evaluation of Rosa germplasm resources and analysis of floral fragrance components in R. rugosa

Cheng, X. R., Feng, Y., Chen, D., Luo, C. S., Yu, X., & Huang, C. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.1026763 · Cited by 27 · see citing works

Chemical and Molecular Aspects on Interactions of Galanthamine and Its Derivatives with Cholinesterases

Gülcan, H. O., Orhan, İ. E., & Şener, B. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666141202105105 · Cited by 27 · see citing works

Acetylcholinesterase inhibition by medicinal plants: A Review

Ranjan, N., & Kumari, M. (2017) · Annals of Plant Sciences · doi:10.21746/aps.2017.06.003 · Cited by 26 · see citing works

Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors

Atanasova, M., Dimitrov, I., Ivanov, S. M., GEORGIEV, B., Berkov, S. H., Zheleva‐Dimitrova, D., & Doytchinova, I. A. (2022) · Molecules · doi:10.3390/molecules27103139 · Cited by 29 · see citing works

Synthesis and cholinesterase inhibition of cativic acid derivatives

Alza, N. P., Richmond, V., Baier, C. J., Freire, E., Baggio, R., & Murray, A. P. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.06.030 · Cited by 24 · see citing works

Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review

Klose, J., Griehl, C., Roßner, S., & Schilling, S. (2022) · Biomolecules · doi:10.3390/biom12050694 · Cited by 23 · see citing works

Anin vitroperspective to cholinesterase inhibitory and antioxidant activity of fiveGentianaspecies andGentianella caucasea

Şenol, F. S., Tuzun, C. Y., Toker, G., & Orhan, İ. E. (2012) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2012.676031 · Cited by 23 · see citing works

Natural sesquiterpen lactones as acetylcholinesterase inhibitors

HAJIMEHDIPOOR, H., MOSADDEGH, M., NAGHIBI, F., HAERI, A., & HAMZELOO-MOGHADAM, M. (2014) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201420130005 · Cited by 22 · see citing works

Prospective neurobiological effects of the aerial and root extracts and some pure compounds of randomly selectedScorzoneraspecies

Şenol, F. S., Açıkara, Ö. B., Çitoğlu, G. S., Orhan, İ. E., Acqua, S. D., & Özgökçe, F. (2014) · Pharmaceutical Biology · doi:10.3109/13880209.2013.872152 · Cited by 21 · see citing works

An alternative antioxidative and enzyme inhibitory agent from Turkey: Robinia pseudoacacia L.

Sarıkürkçü, C., Kocak, M. S., Tepe, B., & Uren, M. C. (2015) · Industrial Crops and Products · doi:10.1016/j.indcrop.2015.10.017 · Cited by 20 · see citing works

Muthi to medicine

Gericke, N. (2011) · South African Journal of Botany · doi:10.1016/j.sajb.2011.08.007 · Cited by 20 · see citing works

HPTLC Finger-Printing and Cholinesterase Inhibitory and Metal-Chelating Capacity of Various Citrus Cultivars and Olea europaea

Şenol, F. S., Ankli, A., Reich, E., & Orhan, İ. E. (2016) · Food Technology and Biotechnology · doi:10.17113/ftb.54.03.16.4225 · Cited by 18 · see citing works

LC–MS quantification of parthenolide and cholinesterase inhibitory potential of selected Tanacetum L. (Emend. Briq.) taxa

Orhan, İ. E., Tosun, F., Gülpınar, A. R., Kartal, M., Duran, A., Mıhoğlugil, F., & Akalgan, D. (2014) · Phytochemistry Letters · doi:10.1016/j.phytol.2014.10.003 · Cited by 17 · see citing works

Exploring in vitro neurobiological effects and high-pressure liquid chromatography-assisted quantitation of chlorogenic acid in 18 Turkish coffee brands

Erdem, S. A., Şenol, F. S., Budakoglu, E., Orhan, İ. E., & Şener, B. (2015) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2015.08.001 · Cited by 14 · see citing works

Role of Acetylcholinesterase Inhibitors and Alzheimer Disease

Saify, Z. S., & Sultana, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50007-6 · Cited by 14 · see citing works

Metabolite Profiling by Hyphenated Liquid Chromatographic Mass Spectrometric Technique (HPLC‐DAD‐ESI‐Q‐TOF‐MS/MS) and Neurobiological Potential of Haplophyllum sahinii and H. vulcanicum Extracts

Karahisar, E., Tuğay, O., Orhan, İ. E., Şenol, F. S., Luca, S. V., Skalicka‐Woźniak, K., & Sahin, M. (2019) · Chemistry & Biodiversity · doi:10.1002/cbdv.201900333 · Cited by 14 · see citing works

Emerging paradigms in Alzheimer's therapy

Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 14 · see citing works

Changes of rat plasma total low molecular weight antioxidant level after tabun exposure and consequent treatment by acetylcholinesterase reactivators

Pohanka, M., Karasová, J. Ž., Musílek, K., Kuča, K., Jung, Y., & Kassa, J. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756361003733613 · Cited by 13 · see citing works

Effect of Trigonella foenum-graecum Linn. seeds methanol extract on learning and memory

Assad, T., Khan, R. A., & Rajput, M. A. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0235-1 · Cited by 12 · see citing works

Swertiamarin, a secoiridoid glycoside modulates nAChR and AChE activity

Pandey, T., Smita, S. S., Mishra, A., Sammi, S. R., & Pandey, R. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111010 · Cited by 12 · see citing works

Vitamin B3-Based Biologically Active Compounds as Inhibitors of Human Cholinesterases

Zandona, A., Lihtar, G., Maraković, N., Miš, K., Bušić, V., Gašo-Sokač, D., Pirkmajer, S., & Katalinić, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218088 · Cited by 12 · see citing works

Research Strategies Developed for the Treatment of Alzheimer’s Disease. Reversible and Pseudo-Irreversible Inhibitors of Acetylcholinesterase: Structure-Activity Relationships and Drug Design

Palafox, M. A., Posada-Moreno, P., Ortuño‐Soriano, I., del Cerro, J. L. P., Martínez-Rincón, C., Rodrı́guez-Martı́nez, D., & Pacheco-Cuevas, L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50008-8 · Cited by 11 · see citing works

Therapeutic Interventions in Alzheimer Disease

Mitra, A., & Dey, B. (2013) · InTech eBooks · doi:10.5772/54915 · Cited by 10 · see citing works

Recent Advances in the Treatment and Management of Alzheimer’s Disease: A Precision Medicine Perspective

Shukla, D., Suryavanshi, A., Bharti, S. K., Asati, V., & Mahapatra, D. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266299847240328045737 · Cited by 10 · see citing works

Yuccalechins A–C from the Yucca schidigera Roezl ex Ortgies Bark: Elucidation of the Relative and Absolute Configurations of Three New Spirobiflavonoids and Their Cholinesterase Inhibitory Activities

Pecio, Ł., Alilou, M., Kozachok, S., Orhan, İ. E., Eren, G., Şenol, F. S., Stuppner, H., & Oleszek, W. A. (2019) · Molecules · doi:10.3390/molecules24224162 · Cited by 8 · see citing works

Exploring medicinal plants for the development of natural enzyme inhibitors

Naz, S., Holloway, P., Ata, A., & Şener, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85542-6.00005-6 · Cited by 7 · see citing works

Movement disorders associated with acetylcholinesterase inhibitors in Alzheimer’s dementia: A systematic review

Rissardo, J. P., & Caprara, A. L. F. (2025) · Brain Circulation · doi:10.4103/bc.bc_134_24 · Cited by 7 · see citing works

Recent Approaches Towards Selected Lamiaceae Plants for Their Prospective Use in Neuroprotection

Orhan, İ. E., Şenol, F. S., & Şener, B. (2012) · Studies in natural products chemistry · doi:10.1016/b978-0-444-59530-0.00014-9 · Cited by 7 · see citing works

Validation of the spiritual and religious attitudes in dealing with illness (SpREUK) in Portuguese Alzheimer‘s patients

Pereira, M. G., Vilaça, M., Pedras, S., Vieira, S., & Lima, S. (2019) · Journal of Religion Spirituality & Aging · doi:10.1080/15528030.2019.1610989 · Cited by 7 · see citing works

Synthesis of novel Schiff base derivatives of tacrine and investigation of their acetylcholinesterase inhibition potency

Koyuncu, E. A., Yaşar, A., Arslan, F., & Sarı, N. (2019) · Macedonian Journal of Chemistry and Chemical Engineering · doi:10.20450/mjcce.2019.1561 · Cited by 7 · see citing works

Green synthesis of Tacrine modified Schiff bases as anti-Alzheimer Agents: An effective strategy validated through in-silico and in-vitro analysis

Presenjit, P., Chaturvedi, S., Akanksha, Sharma, D., Chaudhary, R., Verma, P., Singh, A., & Singh, K. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100759 · Cited by 6 · see citing works

Antioxidant and anticholinesterase effects of frequently consumed cereal grains usingin vitrotest models

Şenol, F. S., Kan, A., Çoksarı, G., & Orhan, İ. E. (2011) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2011.641943 · Cited by 6 · see citing works

Synthesis and biological evaluation of novel hydrazone derivatives for the treatment of Alzheimer's disease

Ali, S. H., Osmani̇ye, D., & Kaplancıklı, Z. A. (2025) · RSC Advances · doi:10.1039/d5ra05755h · Cited by 5 · see citing works

Investigation of Euphorbia nivulia-HAM for Enzyme Inhibition Potential in Relation to the Phenolic and Flavonoid Contents and Radical Scavenging Activity

Younus, M., Mohtasheem-ul-Hasan, M., Ijaz, S., Kamran, M. A., Maqsood, A., Saddique, B., Nisar, U., Ashraf, M., Mahmoud, E. A., El-Sabrout, A. M., et al. (2022) · Life · doi:10.3390/life12020321 · Cited by 5 · see citing works

Alkaloids and Inhibitory Effects Against Enzymes Linked to Neurodegenerative Diseases (Physostigmine, Galanthamine, Huperzine, etc.)

Orhan, İ. E., & Şenol, F. S. (2013) · Springer eBooks · doi:10.1007/978-3-642-22144-6_23 · Cited by 5 · see citing works

Mitochondrial Dysfunction in Autistic Children and Oral Coenzyme Q10 Supplementation Treatment

Mousavinejad, E., & Ghaffari, M. A. (2016) · Autism - Open Access · doi:10.4172/2165-7890.1000189 · Cited by 5 · see citing works

Biological activity studies on Klasea serratuloides (DC) Greuter & Wagenitz subsp. karamanica B. Dogan & A. Duran extracts obtained with different extraction methods

Eruygur, N., Ayaz, F., Bağcı, Y., Doğu, S., DOĞRU, T., & Koçak, M. (2021) · International Journal of Secondary Metabolite · doi:10.21448/ijsm.942102 · Cited by 4 · see citing works

Neuromodulatory Effect of Plant Metabolites

Barman, D., Dey, N., Sen, S., Kakoti, B. B., & Vanlalhriatpuii, C. (2022) · Sciences of Phytochemistry · doi:10.58920/sciphy01010047 · Cited by 4 · see citing works

Tris-diamine-derived transition metal complexes of flurbiprofen as cholinesterase inhibitors

Jamil, M. A., Sultana, N., Ashraf, R., Sarfraz, M., Tariq, M. I., & Mustaqeem, M. (2018) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v17i3.10 · Cited by 3 · see citing works

Atividade antioxidante, anticolinesterásica e perfil metabolômico de diferentes tipos de pimentas: Implicações na doença de Alzheimer

Biazotto, F. D. O. (2014) · doi:10.11606/d.11.2014.tde-10112014-112458 · Cited by 3 · see citing works

Immunotherapies: A Treasure Trove of Alzheimer's Disease

Kolay, A., Neelam, N., Gupta, P., Shaikh, A. M., Goel, R., Nagpal, D., & Chitme, H. R. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010308600240709052539 · Cited by 2 · see citing works

Unlocking the Impact of Phyto-bioactive Compounds against Neurodegenerative Disorders

Rahaman, S. M., Ashique, S., Bhowmick, M., Mollick, M., Bhowmick, P., & Kumar, P. (2024) · Nanoscience &amp Nanotechnology-Asia · doi:10.2174/0122106812320650241015153325 · Cited by 2 · see citing works

The rapeutic impact of alkaloids in neurological diseases: A promising key molecule

Kaur, S., Kaur, G., Rana, R., Kumar, B., Melkani, I., Kumar, S., Pandey, N. K., Singh, S., Baghel, D. S., Joshi, K., et al. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202455601004 · Cited by 2 · see citing works

Anticholinesterases Traits Inbuilt in Buxaceae Plant Extracts against Alzheimer’s Disease

Patočka, J., Sharma, S., Navrátilová, Z., Singh, N., Jelínková, R., Mehboob, N., Olekšák, P., Nepovimová, E., & Kuča, K. (2025) · Current Neuropharmacology · doi:10.2174/1570159x23666250326091016 · Cited by 1 · see citing works

Mitochondrial DNA, anti-tuberculosis drugs-induced hepatotoxicity and Alzheimer's disease

Schuck, P. F. (2014) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-37652014862

Avaliação in vitro do potencial antiviral de extratos da planta Guettarda angelica Mart. Ex Müll. Arg. frente a vírus animais

Barros, A. V. (2011) · doi:10.47749/t/unicamp.2011.834074

Bioactive Compounds and Essential Oils as Acetylcholinesterase Inhibitors

Kurgat, E., & Ghareeb, D. A. (2019) · American Journal of Biomedical and Life Sciences · doi:10.11648/j.ajbls.20190706.15

Haplotype-resolved genome assembly provides insights into the floral scent of Rosa rugosaPreprint

Cheng, X. R., Gao, D., Wang, H., Wang, G., Chen, D., Luo, C. S., Liu, H., Wang, T., Jiao, C., Zhang, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2757151/v1

Developing multifaceted drug synergistic therapeutic strategy against neurological disorders

Irum, I., Khan, F., Sufyan, M., Ali, S. H. B., & Rehman, S. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109495

Inhibitory Effects of Alkaloids Against Enzymes Linked to Neurodegenerative Diseases

Orhan, İ. E., & Deniz, F. S. S. (2025) · Springer eBooks · doi:10.1007/978-3-642-36202-6_23-1

Alzheimer Hastalığının Patogenezinde Sideritis L. (Dağçayı) Türlerinin Biyokimyasal ve Moleküler Etkileri

Değirmenci, U. (2025) · Harran Üniversitesi Tıp Fakültesi Dergisi · doi:10.35440/hutfd.1555225

Haplotype-resolved genome assembly provides insights into the unique floral scent of Rosa rugosa originated in China

Cheng, X., Geng, X., Gao, D., Wang, H., Wang, G., Chen, D., Gao, K., Wang, T., Jiao, C., Jiang, B.-B. J., et al. (2026) · Molecular Horticulture · doi:10.1186/s43897-025-00210-x

AChE inhibitors

Kim, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45844-6.00015-9

Novel pyrimidine-based N-Acylhydrazones as dual AChE inhibitors and antioxidants targeting Alzheimer's disease

Moaty, M. N. A. A., Moustafa, A., Hegazy, A. S., Sobhy, A. A., Ghareeb, D. A., Awad, L. F., & Ibrahim, N. A. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110578

BindingDB Entry 50043586: Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.

BindingDB (2014) · UC San Diego · doi:10.7270/q2pg1t56

BindingDB Entry 50045214: Synthesis and cholinesterase inhibition of cativic acid derivatives.

BindingDB (2016) · UC San Diego · doi:10.7270/q2vt1tqc

BindingDB Entry 50001549: 2-Arylbenzofurans from Artocarpus lakoocha and methyl ether analogs with potent cholinesterase inhibitory activity.

BindingDB (2020) · UC San Diego · doi:10.7270/q2x3510b

AVALIAÇÃO DOS EFEITOS DE COMPOSTOS POLIFENÓLICOS EM PARÂMETROS BIOQUÍMICOS E NO TRATAMENTO DE DÉFICITS COGNITIVOS ASSOCIADOS À ADMINISTRAÇÃO DE ESCOPOLAMINA EM PEIXE ZEBRA ( Danio rerio )

Richetti, S. K. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Anti-Acetylcholinesterase Derivatives: A Privileged Structural Framework in Drug Discovery to Treat Alzheimer’s Disease

Bhardwaj, M., Patil, V. M., Dhiman, R., Gupta, S. P., & Masand, N. (2019) · Current Enzyme Inhibition · doi:10.2174/1573407215666190111150241 · Cited by 3 · see citing works

Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update

Tumiatti, V., Bolognesi, M. L., Minarini, A., Rosini, M., Milelli, A., Matera, R., & Melchiorre, C. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.4.387 · Cited by 33 · see citing works

Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease

Kumar, G., K., P. G., Poornima, D. V., Shantaram, M., & Ranjita, G. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100154 · Cited by 88 · see citing works

Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment

Musiał, A., Bajda, M., & Malawska, B. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782023217 · Cited by 195 · see citing works

Medicinal Plants Anti-cholinesterase Activity and the Potential for Alzheimer’s Disease Treatment

Usman, K. (2017) · Journal of Diseases and Medicinal Plants · doi:10.11648/j.jdmp.20170304.12 · Cited by 5 · see citing works